This product is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the Food and Drug Administration.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before using herbs, especially if you are pregnant, nursing, taking medications, or have a medical condition.
PubMed · Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt.,Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties. (2005)
PubMed · Safety and efficacy of echinacea (Echinacea angustafolia, e. purpurea and e. pallida) during pregnancy and lactation. (2006)
Reviewed by: HerbAlly Editorial Team, Medical herbalists and healthcare professionals
How does Echinacea pallida stimulate the immune system?
Echinacea pallida works through several immune-modulating mechanisms. Its active compounds, particularly caffeic acid esters like echinacoside and polyacetylenes, stimulate macrophage activity and enhance phagocytosis. The herb increases production of white blood cells and promotes the release of cytokines that coordinate immune responses. Research (Evidence Level B) suggests these compounds also possess antiviral and anti-inflammatory properties. Unlike Echinacea purpurea, E. pallida contains higher concentrations of echinacoside, contributing to its distinct immunomodulatory profile. Native Americans traditionally used the root for wound healing and immune support long before modern research confirmed these mechanisms.
Does Echinacea pallida interact with any medications?
Echinacea pallida has potential interactions with several medication classes. Its immune-stimulating properties may reduce the effectiveness of immunosuppressant drugs like cyclosporine, prednisone, and other corticosteroids. Theoretically, it could interact with medications metabolized by liver enzymes (CYP450), potentially altering drug levels in the blood. Patients taking antifungal medications, HIV protease inhibitors, or chemotherapy drugs should exercise caution. Those on blood-thinning medications should consult a healthcare provider, as Echinacea may affect clotting. Always disclose all herbal supplement use to your healthcare provider and pharmacist to screen for potential interactions.
What is the recommended dosage of Echinacea pallida for adults?
The typical adult dosage of Echinacea pallida depends on the preparation form. For liquid tincture, 2-5 mL taken three times daily is standard. For dried root extracts, 300-500 mg three times daily is commonly recommended. German Commission E guidelines support these dosage ranges for immune support during acute infections. Treatment duration should be limited to 7-10 days for acute conditions, as prolonged use beyond 8 weeks is not recommended due to potential safety concerns and diminishing effectiveness. Always follow product label instructions and consult a qualified herbalist or healthcare provider for personalized dosing guidance.
Is Echinacea pallida safe to take during pregnancy and breastfeeding?
Echinacea pallida is considered unsafe during pregnancy and should be avoided. While limited studies on other Echinacea species suggest possible short-term safety during pregnancy, E. pallida specifically lacks sufficient safety data. The herb's immune-stimulating properties could theoretically affect fetal development or pregnancy outcomes. Breastfeeding women should also avoid Echinacea pallida, as active compounds may pass into breast milk. Pregnant or nursing individuals should consult their healthcare provider before using any herbal supplements. Those with autoimmune conditions or allergies to plants in the Asteraceae family should similarly avoid this herb.
What are the side effects and contraindications of Echinacea pallida?
Common side effects of Echinacea pallida include mild gastrointestinal upset, nausea, and occasional diarrhea. Allergic reactions, particularly skin rashes, can occur—especially in individuals sensitive to plants in the Asteraceae family (ragweed, daisies, marigolds). Contraindications include autoimmune conditions such as lupus, rheumatoid arthritis, and multiple sclerosis, as immune stimulation may worsen these conditions. People with known allergies to Echinacea or related plants should avoid it entirely. Long-term use beyond 8 weeks is not recommended due to potential liver effects and diminishing immune benefits. Discontinue use immediately if adverse reactions occur.
PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 29 PubMed articles · model: gemma4:31b
Summary
Echinacea pallida is a medicinal herbaceous flowering plant from North America used primarily for its immunomodulatory, antibacterial, and antiviral properties [PMID:35567246, PMID:39452214].
Background
Echinacea pallida (also known as pale purple coneflower) is one of three medicinal species within the Echinacea genus of the Asteraceae family originally from North America [PMID:35567246, PMID:12808356].
Traditional uses
Traditional uses by indigenous Indians include external application for burns, wounds, and insect bites; chewing roots for throat infections and toothache; and internal application for coughs, stomach cramps, pain, and snake bites [PMID:12808356].
Active compounds
Bioactive compounds include high molecular weight polysaccharides (e.g., arabinogalactan) and lower molecular weight compounds such as alkylamides, caffeoyl conjugates (e.g., cichoric acid, echinacoside), and flavonoids [PMID:30000869, PMID:30142565, PMID:39452214].
Mechanism of action
Echinacea pallida modulates immune responses by enhancing macrophage and natural killer cell activity, stimulating cytokine production and phagocytosis [PMID:39452214]. It has been shown to inhibit nitric oxide (NO) production in LPS-activated RAW 264.7 macrophage cells by increasing arginase activity [PMID:19111603] and can inhibit LPS-induced inflammation via the MAPK pathway [PMID:36117511].
Clinical evidence
Evidence CUpper respiratory infections
Commonly used orally to treat or prevent upper respiratory infections [PMID:30000869, PMID:15330011]
Evidence DHerpes Simplex Virus (HSV-1, HSV-2)
Hydroalcoholic extracts and pressed juice exhibited high levels of antiviral activity in vitro, with pressed juice showing the highest activity [PMID:19790030]
Evidence DImmune Function (Animal Model)
In mice, alcohol extracts increased percentages of CD49+ and CD19+ lymphocytes in the spleen and increased natural killer cell cytotoxicity and antibody response to sheep red blood cells [PMID:17887935]
Evidence DCancer Cell Viability (In Vitro)
Hexanic root extract reduced viability of human pancreatic (MIA PaCa-2) and colon (COLO320) cancer cells, with E. pallida being the most active species [PMID:17052874]
Safety & adverse effects
Generally well tolerated, though reports include gastrointestinal upset, diarrhea, constipation, skin rash, and rare allergic reactions [PMID:30000869, PMID:26441065]. In a 7-day rat study, subtle alterations were observed in relative liver weight, alkaline phosphatase (ALP), and platelet count [PMID:38454746].
Pregnancy & lactation
No data exist on the safety and efficacy of Echinacea in nursing mothers or infants, although excretion of some alkamides was found in breastmilk in one mother [PMID:30000869].
Drug interactions
It may alter the metabolism of some drugs metabolized by the P450 enzyme system [PMID:30000869].
Evidence summary
The evidence consists primarily of in vitro studies, animal models, and literature reviews (Levels C and D), with limited clinical trial data provided in the abstracts.
PubMed sources
1.PMID: 30000869 (2006) — Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt.,Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties. · The Journal of pharmacy and pharmacology
2.PMID: 35567246 (2022) — Echinacea purpurea (L.) Moench: Biological and Pharmacological Properties. A Review. · Plants (Basel, Switzerland)
3.PMID: 26763832 (2016) — Rabbit dietary supplementation with pale purple coneflower. 2. Effects on the performances, bacterial community, blood parameters and immunity of growing rabbits. · Animal : an international journal of animal bioscience
4.PMID: 30727409 (2012) — First Report of a 16SrII-A Subgroup Phytoplasma Associated with Purple Coneflower (Echinacea purpurea) Witches'-Broom Disease in Taiwan. · Plant disease
No direct government monograph is available for this herb. The content below is AI-generated and has not been verified against an authoritative government source. Use the search links to check official sources before relying on this information.
— Complementary and alternative interventions in asthma, allergy, and immunology.
· Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
6.PMID: 26763800 (2016) — Rabbit dietary supplementation with pale purple coneflower. 1. Effects on the reproductive performance and immune parameters of does. · Animal : an international journal of animal bioscience
7.PMID: 15386194 (2004) — Monoclonal antibodies against an arabinogalactan-protein from pressed juice of Echinacea purpurea. · Planta medica
8.PMID: 40701268 (2025) — Chicoric acid ameliorates rat salpingitis by inhibiting the Nrf2/Notch1 signaling pathway. · European journal of pharmacology
9.PMID: 14970897 (2004) — [Applied fundamental research of echinacea species]. · Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
10.PMID: 26441065 (2016) — Review and Assessment of Medicinal Safety Data of Orally Used Echinacea Preparations. · Planta medica
11.PMID: 30142565 (2018) — Analytical methods for the study of bioactive compounds from medicinally used Echinacea species. · Journal of pharmaceutical and biomedical analysis
12.PMID: 25077780 (2014) — Biotechnological production of caffeic acid derivatives from cell and organ cultures of Echinacea species. · Applied microbiology and biotechnology
13.PMID: 39452214 (2024) — Phytochemistry, Mechanisms, and Preclinical Studies of Echinacea Extracts in Modulating Immune Responses to Bacterial and Viral Infections: A Comprehensive Review. · Antibiotics (Basel, Switzerland)
14.PMID: 19957872 (2009) — Herbal supplements and athlete immune function--what's proven, disproven, and unproven? · Exercise immunology review
15.PMID: 23408271 (2013) — Echinacea sanguinea and Echinacea pallida extracts stimulate glucuronidation and basolateral transfer of Bauer alkamides 8 and 10 and ketone 24 and inhibit P-glycoprotein transporter in Caco-2 cells. · Planta medica
16.PMID: 36013466 (2022) — A Review with Updated Perspectives on the Antiviral Potentials of Traditional Medicinal Plants and Their Prospects in Antiviral Therapy. · Life (Basel, Switzerland)
17.PMID: 12808356 (2003) — [History of a plant: the example of Echinacea]. · Forschende Komplementarmedizin und klassische Naturheilkunde = Research in complementary and natural classical medicine
18.PMID: 11155023 (2000) — [Pharmaceutical comparability of different therapeutic Echinacea preperations]. · Forschende Komplementarmedizin und klassische Naturheilkunde = Research in complementary and natural classical medicine
19.PMID: 36117511 (2021) — Co-cultured adventitious roots of Echinacea pallida and Echinacea purpurea inhibit lipopolysaccharide-induced inflammation via MAPK pathway in mouse peritoneal macrophages. · Chinese herbal medicines
20.PMID: 17253306 (1998) — MEKC analysis of different Echinacea species. · Planta medica
21.PMID: 17887935 (2007) — Enhancement of innate and adaptive immune functions by multiple Echinacea species. · Journal of medicinal food
22.PMID: 30731927 (2011) — First Report of a 16SrII-D Subgroup Phytoplasma Associated with Pale Purple Coneflower Witches'-Broom Disease in Australia. · Plant disease
23.PMID: 19101884 (2009) — Metabolic profiling of echinacea genotypes and a test of alternative taxonomic treatments. · Planta medica
24.PMID: 38454746 (2024) — Assessment of clinical chemistry and hematological parameters in female Sprague-Dawley rats following a 7-day oral exposure to three different species of Echinacea. · Journal of environmental science and health. Part C, Toxicology and carcinogenesis
25.PMID: 19111603 (2009) — Echinacea increases arginase activity and has anti-inflammatory properties in RAW 264.7 macrophage cells, indicative of alternative macrophage activation. · Journal of ethnopharmacology
26.PMID: 23181941 (2012) — Seasonal variations in the concentrations of lipophilic compounds and phenolic acids in the roots of Echinacea purpurea and Echinacea pallida. · Journal of agricultural and food chemistry
27.PMID: 17085292 (2006) — Immunomodulatory effects of arabinogalactan-proteins from Baptisia and Echinacea. · Phytomedicine : international journal of phytotherapy and phytopharmacology
28.PMID: 19790030 (2010) — Anti-herpetic properties of hydroalcoholic extracts and pressed juice from Echinacea pallida. · Planta medica
29.PMID: 17052874 (2007) — Cytotoxic effects of Echinacea root hexanic extracts on human cancer cell lines. · Journal of ethnopharmacology